Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
12 Enero 2021 - 5:50AM
Business Wire
Michael
Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation &
Immunology Research Unit at Pfizer, to join Vedanta’s Scientific Advisory
Board
Vedanta Biosciences, a leading clinical-stage company developing
a new category of therapies for immune-mediated diseases based on
rationally defined consortia of human microbiome-derived bacteria,
today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million
investment in Vedanta, as part of the Pfizer Breakthrough Growth
Initiative.
Vedanta intends to use the proceeds to fund a Phase 2 study of
VE202 in inflammatory bowel disease (IBD), which it plans to
initiate in 2021. Topline Phase 1 study data showed VE202 was
generally safe and well-tolerated at all doses and demonstrated
durable and dose-dependent colonization.
“We thank Pfizer for its investment in Vedanta and support of
our IBD program and look forward to advancing microbiome modulation
as a potential new treatment modality for IBD patients,” said
Bernat Olle, Ph.D., Co-founder and Chief Executive Officer of
Vedanta Biosciences.
“Inflammatory bowel disease has a daily, chronic impact on as
many as 1.6 million Americans, and with cases on the rise in the
U.S., patients urgently need new therapeutic options,” said Michael
Vincent, M.D., Ph.D., Senior Vice President and Chief Scientific
Officer, Inflammation & Immunology Research Unit at Pfizer. “We
believe Vedanta’s approach to modulating the microbiome may hold
promise for people living with IBD, and we are excited for its
potential as this important study moves forward.”
As part of the investment, Dr. Vincent will join Vedanta’s
Scientific Advisory Board. Vedanta will retain control of all its
programs and has granted Pfizer a right of first negotiation on
VE202.
About VE202
VE202 is a first-in-class orally administered investigational
live biotherapeutic product (LBP) consisting of a defined bacterial
consortium. It is produced under GMP conditions from pure, clonal
bacterial cell banks, which yield a standardized drug product in
powdered form and bypasses the need to rely on direct sourcing of
fecal donor material of inconsistent composition. VE202 was
designed to induce immune tolerance via the gut and thereby
potentially treat inflammatory bowel disease. Results describing
the biology and candidate selection of VE202 were previously
published in Science and Nature (multiple).
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential
new category of oral therapies based on rationally defined
consortia of bacteria derived from the human microbiome. The
company’s clinical-stage pipeline includes product candidates being
evaluated for the treatment of high-risk C. difficile infection,
inflammatory bowel diseases, advanced or metastatic cancers, and
food allergy. These investigational therapies are grounded in
pioneering research – published in leading journals including
Science, Nature, and Cell – to identify beneficial bacteria that
live symbiotically within the healthy human gut, fight pathogens
and induce a range of potent immune responses. Vedanta Biosciences
controls a foundational portfolio of more than 40 patents and has
built what is believed to be the world’s biggest library of
bacteria derived from the human microbiome. Proprietary
capabilities include deep expertise in consortium design, vast
datasets from human interventional studies and cGMP-compliant
manufacturing of oral live biotherapeutics containing pure,
clonally derived bacterial consortia in powdered form. Vedanta
Biosciences was founded by PureTech Health (LSE: PRTC, Nasdaq:
PRTC) and a global team of scientific co-founders who pioneered
Vedanta’s modern understanding of the cross-talk between the
microbiome and the immune system.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210112005289/en/
Investors and Media Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024